Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551170 · ClinicalTrials.gov registry record · Phase 2
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
A Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT04551170: Active Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, sponsored by Vanderbilt University Medical Center.
NCT04551170 is a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04551170, a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children.
Primary Outcome
BMI expressed as percent of the 95th percentile
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Theophylline
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT04551170 still lists
NCT04551170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Albright Hereditary Osteodystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04551170 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04551170 about?
NCT04551170 is a clinical study titled "Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old". Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in...
What is the current status of trial NCT04551170?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-07-13. Estimated completion is 2026-12-31.
What conditions does trial NCT04551170 study?
This clinical trial studies the following conditions: Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1A.
What interventions are being tested in trial NCT04551170?
The interventions under investigation include: Placebo (DRUG), Theophylline (DRUG).
Who is sponsoring clinical trial NCT04551170?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04551170 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Albright Hereditary Osteodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04551170's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI